NYSE:EBS Emergent Biosolutions Q3 2024 Earnings Report $6.76 +0.10 (+1.42%) Closing price 09/24/2026 03:59 PM EasternExtended Trading$6.68 -0.09 (-1.33%) As of 09/24/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Emergent Biosolutions EPS ResultsActual EPS$1.37Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEmergent Biosolutions Revenue ResultsActual Revenue$10.00 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEmergent Biosolutions Announcement DetailsQuarterQ3 2024Date1/15/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsEmergent Biosolutions' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, October 28, 2026 at 5:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile Emergent Biosolutions Earnings HeadlinesContrasting United Therapeutics (NASDAQ:UTHR) & Emergent Biosolutions (NYSE:EBS)28 minutes ago | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBSSeptember 24 at 6:38 PM | prnewswire.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. | Profits Run (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBSSeptember 22 at 8:46 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBSSeptember 17, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBSSeptember 15, 2026 | globenewswire.comSee More Emergent Biosolutions Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Emergent Biosolutions? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Emergent Biosolutions and other key companies, straight to your email. Email Address About Emergent BiosolutionsEmergent Biosolutions (NYSE:EBS) is a life sciences company focused on developing, manufacturing and supplying medical countermeasures and other products intended to address public health threats. Its activities include vaccines, therapeutics and treatments for infectious diseases, overdoses and other emergency health situations, as well as contract development and manufacturing services for pharmaceutical and biotechnology companies. The company’s portfolio has included BioThrax, an anthrax vaccine, and ACAM2000, a smallpox vaccine supplied primarily for preparedness programs. Emergent also manufactures and commercializes NARCAN naloxone nasal spray, which is used to rapidly reverse the effects of an opioid overdose. Its products and services support government preparedness initiatives, healthcare providers, pharmacies and commercial customers. Founded in 1998, Emergent BioSolutions serves customers in the United States and international markets. The company has historically worked closely with U.S. government agencies, including through public-health preparedness contracts, while also serving private-sector pharmaceutical and biotechnology customers through its manufacturing operations.View Emergent Biosolutions ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure BuildsPaychex Plunges, Providing the Entry Investors Have Been Waiting ForThe Case for Buying High-Yield General Mills Just StrengthenedEnergy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock? Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
